"This is a big deal," says Boris Jordan, founder and executive chairman of the board of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), referring to the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administration (DEA) regarding the rescheduling of cannabis.

In a candid conversation with Maureen Meehan, cannabis editor of Benzinga, Jordan delved deep into his perspectives on the monumental news, the implications for the cannabis industry and the role politics might play in the months ahead.

If you are interested in hearing more about these topics, the upcoming Benzinga Cannabis Capital Conference in Chicago is honored to have Jordan as a keynote speaker. Mark your calendar for September 27 – 28.

Related Content: DEA's Rescheduling Of Cannabis Will Have Limited Impact On Criminal Justice Reform, Says Advocate

Biden, DEA & Cannabis: Jordan Spells On Legalization's Future

"We've been expecting this for some time," Jordan begins, recollecting the last significant rally in the cannabis markets when President Joe Biden voiced his support for a re-evaluation of the status of cannabis.

Jordan acknowledges …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.